Du, J., Kong, X., Sha, H., Bai, X., Liu, Y., Gao, Y., Kong, W., Liu, B. (2026). Integrated NAL-IRI/5-FU/LV, benmelstobart, anlotinib with or without immunoradiotherapy for second-line metastatic pancreatic cancer: A phase II dual-cohort study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16374